Show simple item record

dc.contributor.authorPhillips, EH
dc.contributor.authorDevereux, S
dc.contributor.authorRadford, John A
dc.contributor.authorMir, N
dc.contributor.authorAdedayo, T
dc.contributor.authorClifton-Hadley, L
dc.contributor.authorJohnson, R
dc.date.accessioned2019-03-29T14:22:22Z
dc.date.available2019-03-29T14:22:22Z
dc.date.issued2019en
dc.identifier.citationPhillips EH, Devereux S, Radford J, Mir N, Adedayo T, Clifton-Hadley L, et al. Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial. Leuk Lymphoma. 2019 Feb 18:1-4.en
dc.identifier.pmid30773077en
dc.identifier.doi10.1080/10428194.2019.1576870en
dc.identifier.urihttp://hdl.handle.net/10541/621616
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1080/10428194.2019.1576870en
dc.titleToxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentCancer Research UK and University College London Cancer Trials Centre , London , UKen
dc.identifier.journalLeukemia & Lymphomaen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record